Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Treasury Shares (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Treasury Shares for 7 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares fell 1.28% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 1.28% decrease, with the full-year FY2025 number at $2.5 million, down 1.28% from a year prior.
  • Treasury Shares was $2.5 million for Q4 2025 at Beam Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.4 million in Q1 2024 to a low of $1.1 million in Q4 2021.
  • A 5-year average of $2.2 million and a median of $2.2 million in 2023 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 38.79% in 2021, then soared 72.92% in 2023.
  • Beam Therapeutics' Treasury Shares stood at $1.1 million in 2021, then soared by 50.31% to $1.7 million in 2022, then skyrocketed by 72.92% to $2.9 million in 2023, then fell by 11.97% to $2.6 million in 2024, then decreased by 1.28% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Treasury Shares are $2.5 million (Q4 2025), $2.8 million (Q3 2025), and $2.9 million (Q2 2025).